Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT278 vs NovoRapid in Type 1 Diabetes
NCT04660305Phase 1Completed
- Sponsor
- Arecor Therapeutics
- Start
- Dec 2020
- Primary completion
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AT278 in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Arecor Therapeutics. Primary endpoint: Area Under the Glucose Infusion Rate Curve (0-8 hours). Started Dec 2020; status: completed.
02
Drugs
AT278
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04660305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04660305.